Australia Recalls Anti-inflammatory Drug Prexige After Two Deaths

by VR Sreeraman on August 11, 2007 at 8:25 PM
Australia Recalls Anti-inflammatory Drug Prexige After Two Deaths

Australia's drugs watchdog said Saturday it had ordered the recall of the anti-inflammatory medication Prexige after it was linked to two deaths.

The Therapeutic Goods Administration (TGA) said Australia was the first country to withdraw the drug, which is in the same class of pharmaceuticals as Vioxx, withdrawn by manufacturer Merck in 2004.


Technically called lumiracoxib, Prexige is produced by the Switzerland-based company Novartis AG, which said it had contacted health authorities in 50 countries where the drug is sold about the withdrawal.

The move followed a review of eight cases where people suffered severe liver damage after using the drug. Two of those people died and another two required liver transplants.

"As a result of those case reports we have taken this straight to our drug safety committee who met yesterday," said Rohan Hammett, the TGA's principal medical adviser.

"They recommended that it immediately be deregistered."

Australia was the first country to recall the drug, Hammett said.

Prexige is taken by about 60,000 people in Australia and is prescribed for osteoarthritis, post-operative pain, pain related to dental procedures and painful menstruation.

The TGA has recommended people taking Prexige seek an alternative medication and have liver function blood tests. It is a non-steroidal anti-inflammatory drug, technically called a Cox-2 inhibitor.

Another Cox-2 inhibitor, Vioxx or Rofecoxib, was voluntarily recalled by manufacturer Merck in 2004 due to adverse health conditions in patients taking it.

"Regulators around the world have been watching this class of drugs very closely since Vioxx and hence we've acted very quickly," Hammett said.

Novartis said it supported the decision.

"Cleary, patient safety is of the utmost importance," said Nick Kurstjens, the company's chief scientific officer for Australia.

Source: AFP
Font : A-A+



Recommended Readings

Latest Drug News

Anti-Obesity Drugs' Impact on Osteoarthritis Survival
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Can a Needle-Free Patch Transform Zika Protection?
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Australia Recalls Anti-inflammatory Drug Prexige After Two Deaths Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests